Success of Vaccine Offers Promise of Cervical Cancer Prevention
Open Access
- 15 January 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 95 (2) , 102-104
- https://doi.org/10.1093/jnci/95.2.102
Abstract
Although researchers are not yet ready to declare victory over cervical cancer, one crucial battle may have been won. In late November, pharmaceutical maker Merck & Company Inc. announced that, 2 years into a planned 4-year proof-of-principle study, the company’s investigational vaccine against human papillomavirus type 16 (HPV16) is working exactly as designers had hoped: It eliminated the risk of infection with HPV16 in 100% of women who were not previously infected.Keywords
This publication has 0 references indexed in Scilit: